Indivior Announces FDA Approval of Label Changes for SUBLOCADE® (buprenorphine extended-release) Injection
Rapid Initiation Protocol Reduces Time to Treatment with SUBLOCADE® From One Week to One Hour, A Significant Advancement in the Treatment of Moderate to Severe Opioid Use Disorder (OUD)
RICHMOND, Va., Feb. 24, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV), a global leader in addiction treatment, today announced that the U.S. Food and Drug Administration (FDA) has approved label changes for SUBLOCADE® including a rapid initiation protocol and alternative injection sites, marking a significant advancement in the treatment of moderate to severe opioid use disorder (OUD).
Key Label Changes Include:
Rapid initiation Protocol: Healthcare providers can now initiate treatment with SUBLOCADE after a single dose of transmucosal buprenorphine and a one-hour observation period to confirm tolerability.1,2
Alternative Injection Sites: SUBLOCADE can now be administered subcutaneously in the abdomen, thigh, buttock, or back of the upper arm, offering patients and healthcare providers increased flexibility in treatment administration2.
These FDA label changes can provide important benefits for patients and healthcare providers. Rapid initiation may lessen some of the practical obstacles to treatment induction, which may increase the likelihood that patients and providers will start therapy quickly, thereby shortening the time to achieve SUBLOCADE's therapeutic levels that provide continuous buprenorphine concentrations above 2ng/mL.3
Additionally, the ability to select a different injection site may provide patients more flexibility so that they may be inclined to continue their treatment. More options for healthcare providers to administer SUBLOCADE will streamline the course of treatment and improve integration into different healthcare environments.
"These label updates for SUBLOCADE underscore our dedication to evolving our treatment options to better serve individuals battling opioid use disorder," said Dr. Christian Heidbreder, Ph.D., Chief Scientific Officer at Indivior. "These enhancements not only reflect our commitment to patient-centered care but also our ongoing efforts to align our treatments with real-world clinical needs, thereby potentially improving patient adherence and outcomes."
Indivior is committed to empowering patients on their path to recovery by providing treatments that are both effective and tailored to their medical needs. These label changes do not alter the well-established safety profile or the efficacy of SUBLOCADE and the medication continues to offer an effective treatment option for OUD while being more adaptable to patient medical needs.
The non-inferiority study supporting rapid induction with SUBLOCADE was conducted across multiple sites, included 729 participants (mean age 40.7, average opioid use of 15 years)1, and was stratified by fentanyl presence in urine screens. At induction 77.5% of patients were fentanyl-positive. Patients were randomized at a 2:1 ratio to rapid initiation [received a single dose of 4 mg transmucosal buprenorphine (TM-BUP), followed by a SUBLOCADE injection within one hour] or to a standard induction (daily TM-BUP over ≥7 days) before receiving injection 1. Rapid induction was effective, shown by the primary endpoint of participant retention at the second injection. The proportion of participants who received the second injection was 66.4% in the rapid induction arm and 54.5% in the standard induction arm2.
About SUBLOCADE®
SUBLOCADE ® (buprenorphine extended-release) injection, for subcutaneous use, CIII
INDICATION AND HIGHLIGHTED SAFETY INFORMATION
INDICATION
SUBLOCADE is indicated for the treatment of moderate to severe opioid use disorder in patients who have initiated treatment with a single dose of a transmucosal buprenorphine product or who are already being treated with buprenorphine.
SUBLOCADE should be used as part of a complete treatment plan that includes counseling and psychosocial support.
HIGHLIGHTED SAFETY INFORMATION
WARNING: RISK OF SERIOUS HARM OR DEATH WITH INTRAVENOUS ADMINISTRATION; SUBLOCADE RISK EVALUATION AND MITIGATION STRATEGY
Serious harm or death could result if administered intravenously. SUBLOCADE forms a solid mass upon contact with body fluids and may cause occlusion, local tissue damage, and thrombo-embolic events, including life-threatening pulmonary emboli, if administered intravenously.
Because of the risk of serious harm or death that could result from intravenous self-administration, SUBLOCADE is only available through a restricted program call the SUBLOCADE REMS Program. Healthcare settings and pharmacies that order and dispense SUBLOCADE must be certified in this program and comply with the REMS requirements.
CONTRAINDICATIONS
Hypersensitivity to buprenorphine or any other ingredients in SUBLOCADE.
WARNINGS AND PRECAUTIONS
Addiction, Abuse, and Misuse: SUBLOCADE contains buprenorphine, a Schedule III controlled substance that can be abused in a manner similar to other opioids. Monitor patients for conditions indicative of diversion or progression of opioid dependence and addictive behaviors.
Respiratory Depression: Life threatening respiratory depression and death have occurred in association with buprenorphine. Warn patients of the potential danger of self-administration of benzodiazepines or other CNS depressants while under treatment with SUBLOCADE.
Risk of Serious Injection Site Reactions: Likelihood of may increase with inadvertent intramuscular or intradermal administration. Evaluate and treat as appropriate. The most common injection site reactions are pain, erythema and pruritus with some involving abscess, ulceration and necrosis.
Neonatal Opioid Withdrawal Syndrome: Neonatal opioid withdrawal syndrome (NOWS) is an expected and treatable outcome of prolonged use of opioids during pregnancy.
Adrenal Insufficiency: If diagnosed, treat with physiologic replacement of corticosteroids, and wean patient off of the opioid.
Risk of Opioid Withdrawal with Abrupt Discontinuation: If treatment with SUBLOCADE is discontinued, monitor patients for several months for withdrawal and treat appropriately.
Risk of Hepatitis, Hepatic Events: Monitor liver function tests prior to and during treatment.
Risk of Withdrawal in Patients Dependent on Full Agonist Opioids: Verify that patients have tolerated transmucosal buprenorphine before injecting SUBLOCADE.
Treatment of Emergent Acute Pain: Treat pain with a non-opioid analgesic whenever possible. If opioid therapy is required, monitor patients closely because higher doses may be required for analgesic effect.
ADVERSE REACTIONS
Adverse reactions commonly associated with SUBLOCADE (in ≥5% of subjects) were constipation, headache, nausea, injection site pruritus, vomiting, increased hepatic enzymes, fatigue, and injection site pain.
For more information about SUBLOCADE, the full Prescribing information including BOXED WARNING, and Medication Guide, visit www.sublocade.com.
About Opioid Use Disorder (OUD)
Opioid Use Disorder (OUD) is a chronic disease in which people develop a pattern of using opioids that can lead to negative consequences.4 OUD may affect the parts of the brain that are necessary for life-sustaining functions.4
About Indivior
Indivior is a global pharmaceutical company working to help change patients' lives by developing medicines to treat substance use disorders (SUD). Our vision is that all patients around the world will have access to evidence-based treatment for the chronic conditions and co-occurring disorders of SUD. Indivior is dedicated to transforming SUD from a global human crisis to a recognized and treated chronic disease. Building on its global portfolio of OUD treatments, Indivior has a pipeline of product candidates designed to expand on its heritage in this category. Headquartered in the United States in Richmond, VA, Indivior employs over 1,000 individuals globally and its portfolio of products is available in over 30 countries worldwide. Visit www.indivior.com to learn more. Connect with Indivior on LinkedIn by visiting www.linkedin.com/company/indivior.
References
Data on File. Indivior Inc. North Chesterfield, VA.
SUBLOCADE (buprenorphine extended-release) injection, for subcutaneous use [package insert]. North Chesterfield, VA: Indivior PLC; 2025.
Jones AK, Ngaimisi E, Gopalakrishnan M, Young MA, Laffont CM. Population Pharmacokinetics of a Monthly Buprenorphine Depot Injection for the Treatment of Opioid Use Disorder: A Combined Analysis of Phase II and Phase Ill Trials. Clin Pharmacokinet. 2021;60(4):527-540. doi:10.1007/s40262-020-00957-0.
NIDA. 2022, March 22. Drugs and the Brain. Accessed October 30,2023, from https://nida.nih.gov/publications/drugs-brains-behavior-science-addiction/drugs-brain
View original content to download multimedia:https://www.prnewswire.com/news-releases/indivior-announces-fda-approval-of-label-changes-for-sublocade-buprenorphine-extended-release-injection-302382920.html
SOURCE Indivior PLC
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
19 minutes ago
- Yahoo
FDA Reveals Which Kinds of Eggs May Be Contaminated with Salmonella
In a June news release, the U.S. Food and Drug Administration revealed that "brown cage-free and brown certified organic eggs" from the August Egg Company have "the potential" to be contaminated with salmonella. The outlet added that the eggs were "sold under multiple different brand names at restaurants and retailers" and should "no longer be available for sale." Those brands are Clover, First Street, Nuaid, O Organics, Marketside, Raleys, Simple Truth, Sun Harvest, and Sunnyside. According to People, over 1.7 million eggs have been recalled in nine states: California, Washington, Nevada, Arizona, Wyoming, New Mexico, Nebraska, Indiana, and Illinois. On June 6, 2025, the Centers for Disease Control and Prevention revealed they were investigating the "multi-state outbreak of salmonella infections." Mayo Clinic states that while some people with salmonella may have no symptoms, most experience a range of symptoms, like abdominal cramps, within 8 to 72 hours. "In some cases, diarrhea can cause severe dehydration and requires prompt medical attention. Life-threatening complications also may develop if the infection spreads beyond the intestines. The risk of getting salmonella infection is higher with travel to countries without clean drinking water and proper sewage disposal." At this time, 21 people have been hospitalized due to infection, according to the FDA. In a statement, the August Egg Company shared, "We believe it is appropriate out of an abundance of caution to conduct this voluntary recall, as consumers may still have these eggs in their homes. It is important to know that when our processing plant identified this concern, we immediately began diverting all eggs from the plant to an egg-breaking facility, which pasteurizes the eggs and kills any pathogens." The company concluded, "We are committed to addressing this matter fully and to implementing all necessary corrective actions to ensure this does not happen again."FDA Reveals Which Kinds of Eggs May Be Contaminated with Salmonella first appeared on Men's Journal on Jun 7, 2025
Yahoo
2 hours ago
- Yahoo
Salmonella outbreak causes egg recall; 79 people sick
(WTVO) — An egg producer based in California is recalling over a million eggs across nine states due to a salmonella outbreak, according to the (FDA). The specific type of eggs recalled was cage-free brown eggs manufactured by the August Egg Company. Those eggs were sold between February 3 and May 15. Select Walmart locations had the tainted eggs for sale, including stores in Illinois. They are also being recalled at Save Mart, FoodMaxx, Lucky, Smart & Final, Food 4 Less, Smart and Final, Safeway, Raleys and Ralphs. from the U.S. Centers for Disease Control and Prevention show that 79 people fell ill and 21 people went to the hospital in seven states. The specific container had a plant code number of P-6562 or CA5330 printed on the package. Salmonella infections can happen 12 to 72 hours after eating food that is contaminated. Symptoms of Diarrhea, fever and abdominal cramps can last from four to seven days, according to the . Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
4 hours ago
- Yahoo
Food recall: Brown eggs sold at grocery stores across California have salmonella risk
A California company is recalling 1.7 million cartons of brown eggs — sold at stores including Walmart in nine states including California — because the eggs may be contaminated with salmonella bacteria. August Egg Company of Hilmar is recalling 1,700,000 dozen brown cage-free and brown certified organic eggs for potential salmonella risk. The eggs were distributed over the last four months, some with sell by dates as late as June 19, according to the recall notice from the Food and Drug Administration. The eggs are linked to an ongoing Salmonella Enteritidis outbreak in seven states, in which 79 people have been sickened and at least 21 hospitalized, but no deaths have been reported, according to the Centers for Disease Control and Prevention. Most of the people sickened (63) live in California, according to the CDC. Nevada and Washington reported four illnesses each, with additional cases in Arizona (3), New Jersey (2), Nebraska (2), Kentucky (1). Ill people in Kentucky, New Jersey, and Washington reported traveling to California and Nevada before they got sick. Most of those sickened (90%) reported eating eggs, the CDC said. Some samples taken by the FDA during an inspection at August Egg Company's processing facility tested positive for the strain of salmonella similar to those related to the persons sickened in the outbreak, the CDC said. August Egg Co. said its internal food safety team is conducting its own investigation to "identify what measures can be established to prevent this situation from recurring," the company said in a statement accompanying the recall. 'It is important to know that when our processing plant identified this concern, we immediately began diverting all eggs from the plant to an egg-breaking facility, which pasteurizes the eggs and kills any pathogens." USA TODAY Recall Database: Search vehicle, product and food recalls The recalled eggs were distributed beginning Feb. 3 across multiple retailers in nine states: Eggs with sell-by dates to June 4: Through May 15, eggs with those sell-by dates were distributed to Save Mart, FoodMaxx, Lucky, Smart & Final, Safeway, Raleys, Food 4 Less and Ralphs stores in California and Nevada. Eggs with sell-by dates to June 19: Through May 6, eggs with those sell-by dates were distributed to Walmart locations in California, Washington, Nevada, Arizona, Wyoming, New Mexico, Nebraska, Indiana and Illinois. August Egg Co. said consumers can identify the recalled eggs by the plant code on one side of the egg carton. They can return the eggs to the place of purchase for a refund. Consumers with questions can call the company at 1-800-710-2554, between 9 a.m. and 5 p.m. PT. Here's the products recalled with plant code and UPC. Salmonella causes about 1.35 million illnesses, 26,500 hospitalizations, and 420 deaths each year in the U.S., according to the CDC and FDA. Symptoms of salmonella infection – including diarrhea, fever and stomach cramps – typically arise six hours to six days after exposure and may last 4 to 7 days. Severe infections can also include aches, headaches, elevated fever, lethargy, rashes, and blood in the urine or stool. Salmonella poisoning, also known as salmonellosis, is a common gastrointestinal infection in California, with about 5,000 confirmed cases annually, according to the California Department of Public Health. The Centers for Disease Control estimates that around 3,000 people die from a foodborne illness, and of those about 420 people die from Salmonella infections. This article originally appeared on Palm Springs Desert Sun: Egg recall 2025: Salmonella risk for eggs sold at California stores
